Circulation reports · 2026
Optimizing Diagnosis of Transthyretin Amyloidosis Cardiomyopathy in Japan: Care Pathway Barriers and Opportunities.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Endo Jin, Kubo Toru, Suzuki Kota, Tsubota Hiroo, Crawford Emma, Hsu Yuchen
Аннотация
BACKGROUND: Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a progressive, underdiagnosed cause of heart failure, particularly among older adults. Despite updated Japanese Circulation Society (JCS) guidelines and advances in imaging and therapies, diagnostic delays and variability persist. Understanding real-world barriers is essential for improving patient outcomes.
METHODS AND RESULTS: A mixed-methods approach was used to develop an evidenced care pathway for ATTR-CM in Japan. A literature review of guidelines and epidemiological data informed a draft pathway. Semistructured interviews with 5 cardiologists from JCS-certified and regional hospitals explored perceived deviations from guidelines and barriers to care. Thematic analysis highlighted 5 perceived challenges: variability in physician awareness, particularly outside heart failure subspecialties; the influence of symptom type and entry point on diagnostic delay; fragmented referral pathways; low patient awareness and disengagement due to complex processes; and limited access to and interpretation of diagnostic tests.
CONCLUSIONS: Removal of the tissue biopsy requirement for diagnosis and treatment prescription is an important step towards less invasive care and broader treatment access. However, challenges remain in ensuring that non-invasive diagnostic methods are widely available and correctly interpreted. The exploratory findings reported here suggest that addressing awareness gaps, referral fragmentation, and variations in diagnostic expertise may help realize the benefits of non-biopsy diagnosis in Japan.
METHODS AND RESULTS: A mixed-methods approach was used to develop an evidenced care pathway for ATTR-CM in Japan. A literature review of guidelines and epidemiological data informed a draft pathway. Semistructured interviews with 5 cardiologists from JCS-certified and regional hospitals explored perceived deviations from guidelines and barriers to care. Thematic analysis highlighted 5 perceived challenges: variability in physician awareness, particularly outside heart failure subspecialties; the influence of symptom type and entry point on diagnostic delay; fragmented referral pathways; low patient awareness and disengagement due to complex processes; and limited access to and interpretation of diagnostic tests.
CONCLUSIONS: Removal of the tissue biopsy requirement for diagnosis and treatment prescription is an important step towards less invasive care and broader treatment access. However, challenges remain in ensuring that non-invasive diagnostic methods are widely available and correctly interpreted. The exploratory findings reported here suggest that addressing awareness gaps, referral fragmentation, and variations in diagnostic expertise may help realize the benefits of non-biopsy diagnosis in Japan.